Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

On November 15, 2018

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Modification to the Methodology of the S&P ESG Leaders Indices

Modification to the Methodology of the S&P Carbon Control Index Series

MACOM Technology Solutions Holdings Set to Join S&P MidCap 400